Lexicon Enrolls First Patient in Phase 2b Progress Study of LX9211 in Diabetic Peripheral ...

The PROGRESS study marks initiation of the late-stage development program for AAK1 inhibitor LX9211, with potential to become the first new, non-opioid drug therapy in high-unmet need neuropathic pain in

Related Keywords

Texas ,United States ,Alina Cocuzza ,Craig Granowitz ,Lisa Defrancesco ,Bristol Myers Squibb ,Lexicon Pharmaceuticals Inc ,Nasdaq ,Exchange Commission ,Drug Administration ,Lexicon Pharmaceuticals ,Fast Track ,Multicenter Study ,Open Label Extension ,Diabetic Peripheral Neuropathic Pain ,Average Daily Pain Score ,Investor Inquiries ,Media Inquiries ,Region ,